EmendoBio, Inc.
EmendoBio is a New York-based biotechnology company developing the OMNI™ CRISPR nuclease platform. It licenses proprietary nucleases, off-the-shelf compositions, and custom nuclease development services to biopharma partners, and operates as a wholly-owned subsidiary of Japan's AnGes, Inc.
- Company typePrivate
- Founded2016
- HeadquartersNew York, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What EmendoBio, Inc. does
EmendoBio, Inc. (also operating as Emendo Biotherapeutics) is a New York-based biotechnology company developing the OMNI™ nuclease platform for CRISPR-based gene editing therapeutics. Founded around 2015-2016 by Weizmann Institute graduates and headquartered at 111 Town Square Place in Jersey City with an additional office at 400 W 61st St in New York, the company targets the technical limitations of standard CRISPR-Cas9 systems—specifically PAM site constraints, off-target effects, and the inability to perform allele-specific editing. Its core technology is a panel of novel engineered nucleases, including non-NGG PAM variants capable of accessing genomic sites unreachable by common spCas9, coupled with an AI-based computational engineering platform that designs and optimizes nucleases per disease target for high activity and allele specificity. EmendoBio has assembled a multidisciplinary team of 90+ computational biologists, protein engineers, and RNA guide designers, and has built an internal pipeline spanning Severe Congenital Neutropenia (EMD-101, with University of Washington), Familial Hypercholesterolemia and hyperlipidemia (EMD-301/302), and ophthalmic conditions including glaucoma (EMD-201, with Columbia University) and retinitis Pigmentosa (EMD-202/203).
The company monetizes through a B2B licensing and services model targeted at biopharmaceutical companies, biotechnology firms developing cell and gene therapies, and academic research institutions. Revenue streams include out-licensing of OMNI™ nucleases and off-the-shelf gene editing compositions (notably the OMNI-A4™ license to Anocca AB for immuno-oncology applications), custom nuclease development engagements using the AI-based prediction platform, and gene editing consulting services covering gRNA selection and off-target analysis. All terms are negotiated per agreement with no publicly disclosed pricing. EmendoBio was acquired by Japanese biopharmaceutical company AnGes, Inc. in December 2020 and now operates as a wholly-owned subsidiary, following prior venture funding led by OrbiMed with participation from Takeda Ventures. The company remains operationally active, with peer-reviewed scientific publications, ongoing academic collaborations, and an expanding set of licensing partnerships.
EmendoBio, Inc. firmographics
Firmographics- Name
- EmendoBio, Inc.
- Legal name
- EmendoBio, Inc.
- Website
- https://emendobio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- EmendoBio is a New York-based biotechnology company developing the OMNI™ CRISPR nuclease platform. It licenses proprietary nucleases, off-the-shelf compositions, and custom nuclease development services to biopharma partners, and operates as a wholly-owned subsidiary of Japan's AnGes, Inc.
- Ownership category
- akta.pro rank
EmendoBio, Inc. industry classification
Industry- Product category
- CRISPR Gene Editing Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) (HLAAACAD)
- akta.pro secondary industries
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Ophthalmology Gene Therapies (HLAAACAG), CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)
Keywords
Where EmendoBio, Inc. is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
EmendoBio, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Out-licensing of OMNI Nucleases: EmendoBio licenses out their validated OMNI nucleases and gene editing compositions to pharmaceutical and biotechnology companies for therapeutic development.
- Off-the-shelf Gene Editing Compositions: Pre-validated gene editing compositions for target genes available for out-licensing. Solutions can be adjusted to fit customer needs.
- Custom Nuclease Development: Custom nuclease development services using AI-based computational engineering platform to create optimal nuclease variants for unique project requirements.
- Consulting Services: Consulting services in gene editing strategy design, gRNA selection, off-target experiments and analysis, and other gene editing expertise areas.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
EmendoBio, Inc. product offering
Product offeringCore offering
EmendoBio develops and out-licenses the OMNI™ gene editing technology platform, a panel of novel CRISPR nucleases (including non-NGG PAM nucleases) engineered via AI-based computational prediction to deliver high activity, allele specificity, and zero detectable off-target effects. The company licenses these nucleases and pre-validated gene editing compositions to biopharma partners, develops custom nucleases per disease target, and offers gene editing consulting services. It also advances an internal therapeutic pipeline (e.g., EMD-101 for Severe Congenital Neutropenia, ophthalmology and cardiovascular programs).
Product overview
EmendoBio, Inc. is a gene editing company built around the OMNI™ technology platform—a proprietary panel of novel CRISPR nucleases that can be customized for any genetic disease. The platform enables allele-specific editing, a capability that traditional CRISPR nucleases cannot achieve. The product portfolio includes: (1) the OMNI™ Technology Platform itself, which provides nucleases optimized per target gene with high activity and zero detectable off-target effects; (2) Off-the-shelf Gene Editing Compositions for target genes validated across multiple systems; (3) Custom Nuclease Development services using AI-based computational prediction; and (4) Gene Editing Consulting Services. EmendoBio also maintains an internal pipeline of therapeutic programs including EMD-101 for Severe Congenital Neutropenia, EMD-301/302 for cardiovascular diseases, and EMD-201/202/203 for ophthalmology conditions. All offerings are out-licensable to partners seeking to integrate OMNI nucleases into their therapeutic development.
Differentiator
Problem solved
Functional benefit
Products and services
- OMNI™ Technology Platform A gene editing technology platform featuring a panel of novel CRISPR nucleases with various characteristics (including non-NGG PAM nucleases) that enables targeting of any gene with high activity and elimination of off-target effects. Licensed to biopharma and biotech partners for therapeutic development.
- Off-the-shelf Gene Editing Compositions Ready-made CRISPR-based gene editing solutions for multiple target genes validated through computational, cell-line, and target cell systems. Includes allele-specific knockout compositions for various diseases.
- Custom Nuclease Development AI-based computational engineering platform to predict optimal nuclease variants tailored to customer unique project needs, validated through high-throughput screening systems.
- Gene Editing Consulting Services Expert consulting services including gene editing strategy design, gRNA selection, off-target experiments and analysis to optimize approaches and accelerate discoveries.
- EMD-101 (Severe Congenital Neutropenia Program) Lead pipeline indication using allele-specific CRISPR editing for Severe Congenital Neutropenia caused by ELANE mutations. Collaborator: University of Washington.
- EMD-301 (Familial Hypercholesterolemia Program) Cardiovascular program targeting Familial Hypercholesterolemia through gene editing.
- EMD-302 (Hyperlipidemia Program) Cardiovascular program targeting hyperlipidemia through gene editing.
- EMD-201 (Glaucoma Program) Ophthalmology program for glaucoma treatment. Collaborator: Columbia University.
- EMD-202 (Retinitis Pigmentosa Program) Ophthalmology program targeting retinitis pigmentosa through gene editing.
- EMD-203 (Retinitis Pigmentosa Program) Ophthalmology program targeting retinitis pigmentosa through gene editing.
Quantifiable outcome
- Elimination of off-target effects with zero detectable off-targets in optimized nucleases
- +1 more outcomes
Companies that use EmendoBio, Inc.
Customer profileSegments3 records
Ideal customer profiles1 record
EmendoBio, Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
EmendoBio, Inc. partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Anocca ABcoreAnocca AB licensed EmendoBio's OMNI-A4™ gene editing technology. The agreement was expanded in September 2025, granting Anocca broader rights to use the technology for immuno-oncology based therapy development. Anocca is a Swedish biotech company focused on T-cell receptor therapies.
- University of WashingtoncoreUniversity of Washington is a collaborator on EMD-101 (Severe Congenital Neutropenia program). The collaboration focuses on developing allele-specific gene editing therapy for ELANE neutropenia using EmendoBio's OMNI nucleases.
- Columbia UniversitycoreColumbia University is a collaborator on EMD-201 (Glaucoma program), working with EmendoBio on ophthalmic gene editing therapies.
- Seattle Children'sminorSeattle Children's Hospital is listed as a collaborator on EmendoBio's OMNI platform, contributing to the development of novel CRISPR-based therapies.
- Maastricht UniversityminorMaastricht University is listed as a collaborator working with EmendoBio on gene editing research and therapeutic development.
- Antion BiominorAntion Bio is listed as a licensee/collaborator utilizing EmendoBio's OMNI nucleases for their therapeutic development programs.
- Stanford UniversityminorStanford University is listed as a collaborator working with EmendoBio on gene editing research initiatives.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
EmendoBio, Inc. competitors and assessment
Company assessmentDirect peers
- Editas Medicine: Clinical-stage CRISPR gene editing company developing engineered nucleases for rare genetic diseases and oncology. Most directly comparable to EmendoBio in CRISPR-based nuclease engineering and out-licensing/partnership model, though further along clinically.
- CRISPR Therapeutics: Pioneer in CRISPR/Cas9 gene editing with approved therapy Casgevy for sickle cell disease. Comparable to EmendoBio in CRISPR platform-based therapeutic development, though significantly more advanced commercially.
- Beam Therapeutics: Developer of base editing technology — a precision gene editing approach that, like EmendoBio's OMNI platform, aims to expand the scope of editable genomic targets beyond standard CRISPR. Closely comparable in disease-first, precision-editing philosophy.
- Intellia Therapeutics: Clinical-stage company developing in vivo and ex vivo CRISPR/Cas9 gene editing therapies. Comparable to EmendoBio in CRISPR-based therapeutic development for genetic diseases, with a much larger capital base and clinical pipeline.
- Prime Medicine: Developer of prime editing, a next-generation gene editing technology that, like OMNI, seeks to overcome the limitations of standard CRISPR-Cas9. Comparable in next-gen gene editing platform positioning, though focused on prime editing rather than engineered nucleases.
Emerging players
- Verve Therapeutics: Clinical-stage gene editing company focused on cardiovascular disease — directly overlapping with EmendoBio's EMD-301 (Familial Hypercholesterolemia) and EMD-302 (Hyperlipidemia) programs. Comparable in target disease area and gene editing approach.
- Caribou Biosciences: Clinical-stage CRISPR gene editing company with both internal pipeline and a technology licensing platform. Comparable to EmendoBio in pursuing both therapeutic development and platform licensing.
- ToolGen: South Korea-based CRISPR platform company developing engineered nucleases for therapeutic applications. Comparable to EmendoBio as a smaller, platform-focused gene editing company out-licensing CRISPR technology to partners.
Broad incumbents
- Sangamo Therapeutics: Pioneer in genome editing (zinc finger nucleases) now expanding into AAV-based gene therapies and CRISPR partnerships. Comparable as an established gene editing platform player, though with different nuclease technology and broader therapeutic scope.
Others
- AnGes, Inc. Japanese biopharmaceutical company and EmendoBio's parent company since December 2020. Listed as an adjacent peer given the direct ownership relationship and overlapping gene therapy strategic interests.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
EmendoBio, Inc. social profiles
Digital presenceEmendoBio, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
EmendoBio, Inc. leadership team
Management profileNumber of profiles
Profiles4 records
EmendoBio, Inc. funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EmendoBio, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EmendoBio, Inc.
What does EmendoBio, Inc. do?
EmendoBio develops and out-licenses the OMNI™ gene editing technology platform, a panel of novel CRISPR nucleases (including non-NGG PAM nucleases) engineered via AI-based computational prediction to deliver high activity, allele specificity, and zero detectable off-target effects. The company licenses these nucleases and pre-validated gene editing compositions to biopharma partners, develops custom nucleases per disease target, and offers gene editing consulting services. It also advances an internal therapeutic pipeline (e.g., EMD-101 for Severe Congenital Neutropenia, ophthalmology and cardiovascular programs).
Is EmendoBio, Inc. a public or private company?
EmendoBio, Inc. is a private company. It is classified as corporate owned and is currently operating.
When was EmendoBio, Inc. founded?
EmendoBio, Inc. was founded in 2016. It employs 51 to 100 people.
Where is EmendoBio, Inc. based?
EmendoBio, Inc. is headquartered in New York, United States, in the North America region.
How does EmendoBio, Inc. make money?
Four revenue lines are on record. Out-licensing of OMNI Nucleases are the primary driver. The others are off-the-shelf Gene Editing Compositions, custom Nuclease Development and consulting Services.
Who are EmendoBio, Inc.'s main competitors?
Direct peers on record are Editas Medicine, CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics and Prime Medicine. Emerging players are Verve Therapeutics, Caribou Biosciences and ToolGen. Sangamo Therapeutics is listed as a broad incumbent. AnGes, Inc. is listed as an others.
Does EmendoBio, Inc. have an API?
No public API is recorded for EmendoBio, Inc..
What industry is EmendoBio, Inc. in?
EmendoBio, Inc.'s product category is CRISPR Gene Editing Technology. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo), with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 8731.